Filings Radar

SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.

OneMedNet Corp (ONMDW)

CIK 0001849380 3 material events

Insider activity (SEC Form 4)

Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.

Open-market · last 30 days: 2 buyers bought $1000K 1 seller sold $11K
Open-market · last 90 days: 2 buyers bought $2.1M 2 sellers sold $103K
InsiderRoleDateTransactionSharesValue
Yu Jeffrey Chief Medical Officer, Director, 10% Owner 2026-10-09 Open-market buy 45126 $250K
Kosasa Thomas Director, 10% Owner 2026-10-07 Open-market buy 129758 $750K
Green Aaron Chief Executive Officer, Director 2026-09-24 Open-market sell 1667 $11K
Green Aaron Chief Executive Officer, Director 2026-09-22 Open-market sell 5000 $37K
Golden Robert Lawrence Chief Financial Officer, Director 2026-09-21 Open-market sell 3000 $20K
Golden Robert Lawrence Chief Financial Officer, Director 2026-09-15 Open-market sell 3000 $19K
Golden Robert Lawrence Chief Financial Officer, Director 2026-09-14 Open-market sell 2500 $16K
Yu Jeffrey Chief Medical Officer, Director, 10% Owner 2026-09-10 Open-market buy 142857 $90K
Kosasa Thomas Director, 10% Owner 2026-07-30 Open-market buy 1449275 $1000K
Golden Robert Lawrence Chief Financial Officer, Director 2026-07-06 Grant/award 35000 $0
Green Aaron Chief Executive Officer, Director 2026-07-06 Grant/award 65000 $0
Green Aaron Chief Executive Officer, Director 2026-06-23 Open-market buy 36650 $21K
Yu Jeffrey Chief Medical Officer, Director, 10% Owner 2026-06-23 Open-market buy 158730 $100K
Yu Jeffrey Chief Medical Officer, Director, 10% Owner 2026-06-16 Open-market buy 172414 $100K
Green Aaron Chief Executive Officer, Director 2026-06-15 Open-market buy 18702 $10K
Green Aaron Chief Executive Officer, Director 2026-06-12 Open-market buy 36920 $21K
Kosasa Thomas Director, 10% Owner 2026-06-12 Open-market buy 158730 $100K
Kosasa Thomas Director, 10% Owner 2026-05-18 Open-market buy 268817 $250K
Kosasa Thomas Director, 10% Owner 2026-04-23 Open-market buy 280898 $250K
Yu Jeffrey Chief Medical Officer, Director, 10% Owner 2026-04-01 Open-market buy 903614 $750K
Most recent 20 reported transactions. Open-market buys (P) and sells (S) are the deliberate ones; grants and option exercises are compensation. Not investment advice.

Governance Other

8-K filed 2026-09-29 confidence 92%

The filing discloses a 1-for-10 reverse stock split approved by stockholders on September 18, 2026 and effective September 29, 2026, filed under Items 3.03 and 5.03 (amendments to articles of incorporation). The reverse split is intended to bring the company into compliance with Nasdaq's minimum bid price requirement for continued listing. While this is a capital structure modification, it is fundamentally a governance/corporate action matter—an amendment to the certificate of incorporation—rather than a specific named event type. The materiality is clear given the delisting compliance purpose and impact on all shareholders' share counts.

View raw filing on EDGAR →

Shareholder vote

8-K filed 2026-09-23 confidence 95%

The filing discloses results of OneMedNet's 2026 Annual Meeting of Stockholders held on September 18, 2026, with detailed voting tallies for four proposals: election of three Class III directors, ratification of auditor WithumSmith+Brown, approval of an amended 2022 Equity Incentive Plan increasing authorized shares by 1,000,000, and approval of a reverse stock split authorization (1-for-5 to 1-for-20 ratio). Item 5.07 explicitly addresses submission of matters to a vote of security holders, and the filing presents the vote counts and outcomes for each proposal, which is the core disclosure required for shareholder vote results.

View raw filing on EDGAR →

Dilutive issuance

8-K filed 2026-07-01 confidence 92%

OneMedNet entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville on July 1, 2026, granting the option to sell up to $25 million of Common Stock at 97% of market price. The agreement includes an Exchange Cap of 11,386,834 shares (19.99% of outstanding shares), representing a significant dilutive issuance arrangement. This is a classic PIPE-like structure requiring a resale registration statement, disclosed under Item 1.01 as a material definitive agreement.

View raw filing on EDGAR →